MT 400 is POZEN’s proprietary combination of sumatriptan and naproxen sodium, the first multiple mechanism triptan therapy for the treatment of migraine.
MT 400 has been proven to be superior to triptan monotherapy on multiple efficacy endpoints. In a previously published Phase II clinical trial involving 972 patients, MT 400, which uses a marketed triptan and an NSAID, provided a 65 percent improvement for sustained pain relief over triptan monotherapy with a similar side effect profile. Sustained pain relief is defined as patients that achieved pain relief within two hours of dosing and then neither relapsed nor used rescue medicine over the next 22 hours.
POZEN is actively seeking licensing partners for the available territories.